AstraZeneca Etcamah breast cancer trial fails
Analysis based on 8 articles · First reported Sep 11, 2026 · Last updated Sep 12, 2026
The trial failure removes a near-term catalyst for AstraZeneca's oncology pipeline and triggered a 3% drop in its U.S.-listed shares in aftermarket trading, though analysts view the setback as largely priced in and not fundamentally damaging to the long-term investment case. Broader pharmaceutical and biotech sentiment may see modest pressure as investors reassess the risk profile of accelerated-approval oncology drugs pending confirmatory trial data.
AstraZeneca announced on Friday, September 11, 2026, that its breast cancer drug Etcamah (camizestrant) failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial. The drug, tested in combination with Pfizer's cancer drug Ibrance (palbociclib), showed only a numerical, but not statistically significant, improvement in previously untreated patients with a form of advanced breast cancer. The trial involved 1,371 patients with the most common type of advanced breast cancer, in which hormones such as oestrogen fuel cancer growth and which lack high levels of HER2. The result marks a setback for the recently approved treatment, which received accelerated approval from the U.S. United States — Food and Drug Administration just a week earlier for patients whose tumours develop an ESR1 mutation. AstraZeneca said the full trial data will be shared at an upcoming medical meeting. U.S.-listed shares of AstraZeneca fell 3% in aftermarket trading. Analysts at Royal Bank of Canada — RBC Capital Markets and Barclays described the outcome as a manageable and well-anticipated setback that largely clears short-term uncertainty without changing the long-term investment case. Jefferies noted the company sees peak annual sales potential of more than $5bn for the drug, mostly in the early breast cancer setting. The failure echoes a similar setback in March for a comparable drug combination from Roche.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard